KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Income towards Parent Company: 2018-2025

Historic Income towards Parent Company for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to -$32.0 million.

  • Esperion Therapeutics' Income towards Parent Company fell 2.90% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.8 million, marking a year-over-year decrease of 160.12%. This contributed to the annual value of -$4.8 million for FY2024, which is 97.74% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Income towards Parent Company of -$32.0 million as of Q3 2025, which was down 139.04% from -$13.4 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Income towards Parent Company ranged from a high of $58.2 million in Q1 2024 and a low of -$90.9 million during Q1 2021.
  • For the 3-year period, Esperion Therapeutics' Income towards Parent Company averaged around -$27.8 million, with its median value being -$32.0 million (2025).
  • In the last 5 years, Esperion Therapeutics' Income towards Parent Company spiked by 192.46% in 2024 and then tumbled by 171.30% in 2025.
  • Over the past 5 years, Esperion Therapeutics' Income towards Parent Company (Quarterly) stood at -$69.1 million in 2021, then climbed by 17.69% to -$56.8 million in 2022, then dropped by 1.02% to -$57.4 million in 2023, then skyrocketed by 63.71% to -$20.8 million in 2024, then dropped by 2.90% to -$32.0 million in 2025.
  • Its Income towards Parent Company was -$32.0 million in Q3 2025, compared to -$13.4 million in Q2 2025 and -$41.5 million in Q1 2025.